← Back to Search

GLP-1 Receptor Antagonist

Dose A for Hypoglycemia

Phase 1
Waitlist Available
Led By Tracey McLaughlin, MD
Research Sponsored by Tracey McLaughlin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-180 minutes following initiation of ogtt
Awards & highlights

Study Summary

This study is designed to evaluate the safety, efficacy, and pharmacokinetic profile of single ascending doses of exendin 9-39 administered by subcutaneous route in subjects with post-bariatric hypoglycemia.

Eligible Conditions
  • Hypoglycemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-180 minutes following initiation of ogtt
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-180 minutes following initiation of ogtt for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment effect on plasma glucose
Secondary outcome measures
Treatment effect on symptoms of hypoglycemia

Trial Design

4Treatment groups
Active Control
Group I: Dose AActive Control1 Intervention
Subcutaneous injection of Dose A of Exendin (9-39)
Group II: Dose CActive Control1 Intervention
Subcutaneous injection of Dose C of Exendin (9-39)
Group III: Dose DActive Control1 Intervention
Subcutaneous injection of Dose D of Exendin (9-39)
Group IV: Dose BActive Control1 Intervention
Subcutaneous injection of Dose B of Exendin (9-39)

Find a Location

Who is running the clinical trial?

Tracey McLaughlinLead Sponsor
2 Previous Clinical Trials
49 Total Patients Enrolled
2 Trials studying Hypoglycemia
49 Patients Enrolled for Hypoglycemia
Tracey McLaughlin, MDPrincipal InvestigatorStanford University
8 Previous Clinical Trials
520 Total Patients Enrolled
1 Trials studying Hypoglycemia
60 Patients Enrolled for Hypoglycemia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
Tracey McLaughlin 2015. "Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02996812.
All > Hypoglycemia
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top